Abbott

Abbott has announced it received CE Mark in Europe for the Volt Pulsed Field Ablation (PFA) System, intended for treating atrial fibrillation (AFib).

Abbott will release its financial results for the first quarter of 2025 on April 16, before the market opens.

Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System.

Shedd Aquarium and Abbott have announced a significant corporate donation, with Abbott and its philanthropic foundation, Abbott Fund, pledging $10 million.

The board of directors of Abbott has announced a quarterly common dividend of 59 cents per share.